MDCX

Medicus Pharma Ltd. (MDCX) - Form 8-K Summary

Business Context and Reporting Period

Medicus Pharma Ltd., an emerging growth company incorporated in Ontario, Canada, filed this Current Report on Form 8-K on June 17, 2025. The filing details the completion of a debt financing transaction with YA II PN, Ltd. ("Yorkville") under a Securities Purchase Agreement originally signed on May 2, 2025.

Key Financial Metrics and Transaction Details

• Total Debt Issued: $5,000,000 in aggregate principal amount of debentures.
• Total Net Proceeds: $4,500,000 received by the Company across three tranches.
• Interest Rate: 8.00% per annum, subject to an increase to 18.00% upon certain events of default.
• Maturity Date: February 2, 2026.
• Security: Debentures are guaranteed by the Company's subsidiaries via a Global Guaranty Agreement.

Material Changes and Transaction History

The $5,000,000 facility was funded in three stages:

1. May 2, 2025: First tranche of $1,250,000 principal ($1,125,000 net proceeds).
2. June 2, 2025: Second tranche of $1,250,000 principal ($1,125,000 net proceeds) triggered by specific conditions.
3. June 17, 2025: Third and final tranche of $2,500,000 principal ($2,250,000 net proceeds), exhausting the available amount under the agreement.

This filing represents the final drawdown of the committed facility, increasing the Company's direct financial obligations significantly compared to the prior period.

Outlook, Risks, and Management Commentary

The filing does not provide specific forward-looking guidance, revenue projections, or management commentary beyond the execution of the financing. Key risks associated with this transaction include:

• Default Risk: The interest rate may double to 18.00% if certain events of default occur.
• Liquidity Pressure: The entire $5,000,000 principal is due on February 2, 2026, creating a near-term refinancing or repayment obligation.
• Subsidiary Liability: All subsidiaries are jointly liable for the debt under the Global Guaranty.

Investor Verification Checklist

• Verify the specific "events of default" that trigger the interest rate increase to 18.00% in the full text of the Debenture (Exhibit 4.1).
• Confirm the Company's current cash position and burn rate to assess the ability to service the $5,000,000 debt maturing in February 2026.
• Review the "triggers" mentioned in the June 2, 2025 filing to understand the conditions required for the second tranche.
• Check for any subsequent filings regarding the use of the $4.5 million net proceeds.